Could a weekly shot help people with type 1 diabetes lose weight and control blood sugar?

NCT ID NCT05537233

Completed Disease control Sponsor: Viral N. Shah Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested a weekly injection of semaglutide (a drug used for type 2 diabetes and weight loss) in 115 adults with type 1 diabetes and obesity who already use an automated insulin pump. The goal was to see if adding semaglutide helps improve blood sugar levels, reduce hypoglycemia, and lower body weight. Participants received either semaglutide or a placebo for 26 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: semaglutide
What this could lead to: If successful, this could offer a new way to improve blood sugar control and reduce weight in people with type 1 diabetes who are overweight.
What could go wrong: This is a small, early-phase trial (Phase 2) with only 115 participants. Results may not apply to everyone, and semaglutide can cause side effects like nausea or vomiting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder type 1 diabetes mellitus Weight Loss

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY TYPE 1 DIABETES

Contacts and locations

Locations

Barbara Davis Center for Diabetes

Aurora, Colorado, 80045, United States
Harold Schnitzer Diabetes Health Center

Portland, Oregon, 97239, United States
Henry Ford Hospital

Detroit, Michigan, 48202, United States
Iowa Diabetes Research Center

West Des Moines, Iowa, 50265, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.